Article info

Extended report
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

Authors

  1. Correspondence to Professor Philip J Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA, 98122, USA; pmease{at}philipmease.com
View Full Text

Citation

Mease PJ, Fleischmann R, Deodhar AA, et al
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

Publication history

  • Received March 27, 2013
  • Revised June 12, 2013
  • Accepted June 26, 2013
  • First published August 13, 2013.
Online issue publication 
December 04, 2013

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.